Healthcare >> Analyst Interviews >> November 15, 2010
Orphan Drugs:today’s Hot Biotech Story – Dr. Kimberly Lee – Global Hunter Securities, Llc
Dr. Kimberly Lee, D.O., is a Managing Director and Senior Analyst at Global Hunter Securities, LLC, where she focuses on the health care sector. Dr. Lee was most recently a Senior Research Analyst covering biotechnology at Wedbush Securities, identifying and recommending investment ideas to institutional clients, in addition to developing a widely followed annual industry outlook report. While at Wedbush, Dr. Lee received a four-star rating from StarMine for stock picking and performance. Previously she was a Senior Research Analyst at Pacific Growth Equities, LLC, which was acquired by Wedbush, and a Senior Research Associate covering biotechnology at Jefferies & Company, Inc., and Stephens Inc. Dr. Lee earned her Doctor of Osteopathathic Medicine from Kirksville College of Osteopathic Medicine and a Bachelor of Science in biological sciences from Stanford University. She received postdoctoral training in obstetrics and gynecology at Brookdale University Hospital and Medical Center, and Allegheny General Hospital. Profile
TWST: What do you cover in the biotech space?
Dr. Lee: I cover small-cap biotech names. My coverage list includes Ardea Biosciences (RDEA), Auxilium Pharmaceuticals (AUXL), BioSpecifics (BSTC),